Pricing and Market Access Strategy for New Immunology Therapy

Situation

Developed pricing strategy for a therapy entering a crowded market.
Required a clear view of how the evidence package, expected clinical outcomes, and HTA assessments would shape pricing flexibility and access.
Pricing complexity was heightened by multiple doses, titration patterns, and indications across multiple therapeutic areas.

Assessed clinical and HTA outcomes for price and access implications.
Built a revenue model to define price thresholds by market, balancing broad coverage and minimal restrictions with WAC.
Estimated required rebate levels to support target access outcomes.
Developed a competitive landscape of comparator products, including utilization, market share, and cost dynamics, to model expected share capture.
Designed a complex utilization-based rebate approach to account for varying doses, titration patterns, and cross-indication pricing dynamics.

Defined a market-specific pricing strategy to optimize access while preserving value.
Quantified rebate expectations and pricing thresholds needed to support payer coverage goals.
Built a more realistic view of competitive share capture in a crowded market.
Supported decision-making for a complex, multi-indication pricing and contracting strategy.